Peripheral Metabolic Effects of Somatostatin

Peripheral Metabolic Effects of Intra Arterial Somatostatin Infusion in Healthy Controls

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01062529

Enrollment

Registered

2010-02-04

Start date

2009-10-31

Completion date

2010-02-28

Last updated

2013-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acromegaly, Diabetes, Growth Hormone Deficiency

Keywords

GH signalling, insulin resistance, somatostatin, acromegaly

Brief summary

The aim of this study is to investigate peripheral effects of Somatostatin on glucose metabolism and growth hormone (GH) signalling in healthy men. Eight subjects will be enrolled. The hypothesis is that Somatostatin infusion reverses insulin resistance caused by GH.

Interventions

DRUGSomatostatin

4 h of 150 microgram infusion

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

MALE

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* BMI \< 27 kg/m2 * Written informed consent * Healthy

Exclusion criteria

* Any disease * Any use of medications * Present or previous malignancy * Alcohol dependency * Allergy to trial medication

Design outcomes

Primary

Measure	Time frame
Plasma levels of glucose	3 months

Secondary

Measure	Time frame
GH signalling	one year
Serum levels of free fatty acids (FFA)	one year

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026